课题基金 / 基金详情

Signal Transduction and Therapeutics

Signal Transduction and Therapeutics
信号转导和治疗
批准号:
7944561
负责人:
Fuyuhiko Tamanoi
金额:
$7.8万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-04-02 至 2013-11-30

项目摘要

项目成果

Fuyuhiko Tamanoi的其他基金

相似基金

相关文献

中文摘要
翻译
信号转导和治疗计划领域由37名成员组成,涵盖16个成员 加州大学洛杉矶分校内的部门。在过去的竞争周期中,该项目的调查人员创作了374 出版物,其中150份(40%)为计划间出版物,86份(23%)为计划内出版物。143人(38%) 刊登在影响力较大的期刊上。此计划区域的27个成员使用了8个共享资源中的8个 目前由JCCC资助。在本供资年度,经同行审查的资金总额约为1600万美元 总成本,其中包括来自国家癌症研究所的360万美元。与其他计划领域一样,JCCC 促进了许多互动活动和许多支持调查人员的共享资源 STT计划区。在当前的赠款周期内,JCCC以CCSG Development的形式提供的资金 向STT计划领域提供的资金、机构支持和慈善捐赠总额为2,987,635美元。这些资金 支持跨学科资助、种子资助、招聘/保留、计划领域领导支持、 为使用新兴共享资源和受训人员提供资金。二十四名项目区成员 是JCCC支持的接受者。 自1996年成立以来,信号转导计划领域一直致力于调查 正常细胞信号转导的基本机制和肿瘤细胞信号转导的变化。 在当前CCSG资助期内,我们看到翻译研究的活动有所增加, 将基础科学成果转化为临床应用的长期目标。一些活动,包括联合 与临床计划领域的会议,最终信号转导计划领域与 癌症转化性治疗计划领域的一部分成员。这是一种延伸和丰富 程序区现在被称为信号转导和治疗程序区。这些变化 也是对2002年CCSG审查建议的回应,建议更加重视翻译 研究,并与我们的外部咨询委员会进行了广泛的磋商。我们新计划的目标 领域包括:(1)表征信号通路和识别新的信号分子;(2)理解 癌细胞和正常细胞之间信号转导的差异;(3)促进信号转导抑制剂的临床试验; (4)促进基础与临床的密切合作。为了促进这些目标,我们有 开展了一系列计划领域的活动。具体来说,我们组织了三个不同的研讨会系列。 我们继续举办“信号转导和治疗研究”研讨会,以及由 外部扬声器。此外,我们还有一个定期安排的“信号转导和治疗计划” 最后,我们发起了一种新型的会议:“信号转导和 治疗学圆桌讨论会“将基础科学家和临床医生聚集在一起。
英文摘要
The Signal Transduction and Therapeutics Program Area is composed of 37 members, spanning 16 Departments within UCLA. In the past competing cycle, investigators from this Program authored 374 publications, of which 150 (40%) were inter-programmatic and 86 (23%) intra-programmatic. 143 (38%) were placed in high-impact journals. 27 members of this Program Area used 8 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled ~$16 million in total costs, including $3.6 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the STT Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the STT Program Area total $2,987,635. These funds supported Interdisciplinary Grants, Seed Grants, recruitment/retention, Program Area Leadership support, funding for the use of emerging Shared Resources and trainees. Twenty-four of the Program Area Members were the recipients of JCCC support. Since its inception in 1996, the Signal Transduction Program Area has been engaged in investigating both basic mechanisms of signal transduction in normal cells and alterations in signal transduction in tumor cells. During the current CCSG funding period, we have seen increased activity in translational research, with the long-term aim of bringing basic science findings to clinical application. A number of activities, including joint meetings with clinical Program Areas, culminated in the merger of the Signal Transduction Program Area with a portion of the membership of .Cancer Translational Therapeutics Program Area. This extended and enriched Program Area is now called the Signal Transduction and Therapeutics Program Area. These changes were also made in response to the 2002 CCSG review suggestions to place greater emphasis on translational research, and after extensive consultation with our External Advisory Board. The goals of our new Program Area are: (1) to characterize signaling pathways and identify novel signaling molecules; (2) to understand differences in signaling between cancer and normal cells; (3) to promote clinical trials with signaling inhibitors; and (4) to promote close cooperation between basic and clinical science. To facilitate these goals, we have instituted a number of Program Area activities. Specifically, we have organized three different seminar series. We continue with the "Signal Transduction and Therapeutics Research" seminars as well as seminars by outside speakers. In addition, we have a regularly scheduled "Signal Transduction and Therapeutics Program Area Lunch" for our members. Finally, we have initiated a new type of meeting: a "Signal Transduction and Therapeutics Round Table Discussion" to bring together basic scientists and clinicians.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FASEB Summer Conference, July 20-25, 2002
NEUROFIBROMATOSIS TYPE 1 GENE PRODUCT
NEUROFIBROMATOSIS TYPE I GENE PRODUCT
NEUROFIBROMATOSIS TYPE I GENE PRODUCT
  • 批准号:
    3416994
  • 项目类别:
  • 资助金额:
    $18.94万
  • 财政年份:
    1991
  • 负责人:
    Fuyuhiko Tamanoi
  • 依托单位:
海外基金